Bavarian Nordic tumbles after Q3 EBITDA, 2025 orders miss
** Shares in Bavarian Nordic BAVA.CO fall 18% to the bottom of STOXX 600 .STOXX indexafter the Danishvaccine maker posted a lower-than-expected core profit for Q3, 2025 orders below expectations
** Its quarterly EBITDA falls 34% year-on-year to 250 million Danish crowns ($35 million) which Kempen analysts say "dramatically" misses the consensus of 521 million crowns
** Bavarian Nordic says it has so far secured orders worth about 2.40 billion crowns for 2025
** Consensus is now at around 4.30 billion crowns, Sydbank analyst Soren Lontoft Hansen says
** The analyst adds Donald Trump's decision to select Robert Kennedy as the top US health agency leader could also have an impact on the stock
** Bavarian Nordic shares are set for theirworst day since July 2023, wipe away YTD gains
($1 = 7.0676 Danish crowns)
Reporting by Boleslaw Lasocki
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
